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The purpose of this study was to evaluate the occurrence of lymphatic drainage to non-axillary sentinel nodes and to
determine the implications of this phenomenon. A total of 549 breast cancer patients underwent lymphoscintigraphy after
intratumoural injection of
99mTc-nanocolloid. The sentinel node was intraoperatively identiﬁed with the aid of intratumoural
administered patent blue dye and a gamma-ray detection probe. Histopathological examination of sentinel nodes included
step-sectioning at six levels and immunohistochemical staining. A sentinel node outside level I or II of the axilla was found in
149 patients (27%): internal mammary sentinel nodes in 86 patients, other non-axillary sentinel nodes in 44 and both internal
mammary and other non-axillary sentinel nodes in nineteen patients. The intra-operative identiﬁcation rate was 80%. Internal
mammary metastases were found in seventeen patients and metastases in other non-axillary sentinel nodes in ten patients.
Staging improved in 13% of patients with non-axillary sentinel lymph nodes and their treatment strategy was changed in 17%.
A small proportion of clinically node negative breast cancer patients can be staged more precisely by biopsy of sentinel nodes
outside level I and II of the axilla, resulting in additional decision criteria for postoperative regional or systemic therapy.
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Lymph nodes in the internal mammary chain are known to be a
potential site of metastases from breast cancer. Extended radical
mastectomy has been used to obtain information about the status
of these lymph nodes. The internal mammary node status is an
independent prognostic factor for survival (Cody III and Urban,
1995). However, treatment of internal mammary lymph nodes is
subject of debate. The value of elective radiotherapy to these nodes
has never been convincingly shown and is, in fact, the subject of
ongoing randomised studies in Europe and in Canada. Elective
dissection of internal mammary nodes is not done.
Besides the axilla and internal mammary chain, breast cancer
spreads to interpectoral nodes (Rotter’s nodes) in 3–14% of the
patients (Cody III et al, 1984; Dixon et al, 1993; Bale et al,
1999). A Rotter’s node is the only site of metastatic involvement
in a small number of patients (Cody III et al, 1984; Dixon et al,
1993; Bale et al, 1999). The importance of intraparenchymal and
supra- and infraclavicular lymph nodes in breast cancer is
unknown and involvement of these lymph nodes has been
described only incidentally (Hyman and Abellera, 1974; Veronesi
et al, 1987; Nathanson and Wachna, 1999; Rull et al, 1999).
The technique of lymphatic mapping visualises the lymph nodes
that directly receive lymph from a primary breast carcinoma. These
‘sentinel’ nodes can be harvested in the axilla and reﬂect the
tumour-status of the entire axilla with a high sensitivity (Cox et
al, 1998; Doting et al, 2000; Giuliano et al, 2000). The purpose
of this study was to determine the incidence of lymphatic drainage
and metastatic spread to sentinel nodes outside the axilla in early
stage breast cancer and the impact of biopsy of these lymph nodes
on staging and treatment strategy.
PATIENTS AND METHODS
Between January 1997 and July 2001, 549 patients with a clinical
T1-3N0 breast cancer underwent sentinel node biopsy in The
Netherlands Cancer Institute. The mean age was 56 years (range
27–91 years). Six patients had bilateral tumours. Pathologic proof
of breast cancer was routinely obtained. The primary lesion was
still present in all patients. Seventy-one per cent of the patients
underwent wide local excision as part of breast-conserving treat-
ment and the remaining patients underwent mastectomy. The
mean histological tumour diameter was 1.9 cm (range 0.2–
8.0 cm) with a pT1 stage in 82.9%, pT2 in 16.4% and pT3 in
0.7%. Deﬁnitive pathological examination showed ductal
carcinoma in situ without invasion in twelve patients. The ﬁrst
82 patients were part of a learning phase study with conﬁrmatory
axillary lymph node dissection (Doting et al, 2000). In the
subsequent patients, axillary clearance was omitted in case of a
tumour-negative axillary sentinel node.
Sentinel node biopsy
The day before surgery,
99mTc-Nanocolloid (Amersham Cygne,
Eindhoven, the Netherlands) was injected into the tumour in a
mean volume of 0.2 ml and with a mean radioactive dose of
104 Mbq (range 42–159 Mbq). Subsequently, dynamic and static
anterior and prone lateral (hanging breast) images were obtained
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www.bjcancer.com(Valde ￿s Olmos et al, 2000). A hot spot was considered to be a
sentinel node if an afferent lymphatic channel was visualised, the
hot spot was the ﬁrst one seen in a sequential pattern, the hot spot
was the only one in a particular lymph node basin or when a
combination of criteria was present. Intramammary, paramammary
(Gerota) and interpectoral sentinel nodes were deﬁned as interval
nodes, because of their location on the drainage route to the axilla
or internal mammary chain (Caplan, 1975). The location of a
sentinel node was marked on the skin. The following day, patent
blue dye (Blue Patente ￿ V, Laboratoire Guerbet, Aulnay-sous-Bois,
France) in a volume of 1.0 ml was injected into the tumour. The
sentinel node was identiﬁed and harvested after careful dissection
of blue lymphatic vessels and detection of radioactivity with a
gamma ray detection probe (Neoprobe
1, Johnson & Johnson
Medical, Hamburg, Germany). Internal mammary sentinel nodes
were explored through a small transverse incision over the inter-
costal space concerned. After splitting the pectoral muscle ﬁbres
and dividing the intercostal muscles, radioactive lymph nodes with
or without blue discoloration were dissected from the internal
mammary vessels and parietal pleura. It is our policy to perform
a complete axillary lymph node dissection if no sentinel node is
identiﬁed when exploring the axilla unless one is identiﬁed else-
where. Sentinel nodes were formalin-ﬁxated, bisected, parafﬁn-
embedded and cut at a minimum of six levels at 50 to 100 mg
intervals. Parafﬁn sections were stained with haematoxylin-eosin
and immunohistochemistry (CAM5.2, Becton Dickinson, San Jose,
CA, USA).
Postoperative treatment
Traditionally, the indication for radiotherapy of the internal
mammary lymph nodes at our institution was a positive axillary
lymph node irrespective of tumour location and size unless the
patient was enrolled in an ongoing EORTC trial (no. 22922).
Currently, a patient will receive radiotherapy to the parasternal area
if an excised internal mammary sentinel lymph node is tumour-
positive. Adjuvant systemic treatment is generally given to patients
with lymph node metastasis over 2 mm in size. The Dutch national
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Table 1 Lymphatic drainage patterns to axillary and non-axillary sentinel nodes based on
lymphoscintigraphy and the intraoperative use of patent blue dye
With axillary Without axillary
Non-axillary site of sentinel nodes drainage drainage Total
Ipsilateral internal mammary chain 76 9 85
Contralateral internal mammary chain 1 – 1
Intraparenchymal 25 1 26
Interpectoral 5 1 6
Infraclavicular 10 – 10
Supraclavicular 1 – 1
Supraclavicular and intraparenchymal 1 – 1
Ipsilateral internal mammary chain and intraparenchymal 11 – 11
Ipsilateral internal mammary chain and paramammarian 1 1 2
Ipsilateral internal mammary chain and interpectoral 1 2 3
Ipsilateral internal mammary chain and infraclavicular 2 – 2
Ipsilateral mammary chain and supraclavicular – 1 1
Total 134 15 149
Table 2 Results of surgical identiﬁcation of sentinel nodes in the internal
mammary chain and other sites (intramammary, paramammary, interpec-
toral, supra- and infraclavicular)
Internal All
mammary Other non-axillary
chain sites sites
Identiﬁcation rate per patient 90/105 (86%) 50/63 (79%) 128/149 (86%)
Identiﬁcation rate per basin 103/128 (80%) 51/64 (80%) 154/192 (80%)
No. sentinel nodes 126 63 189
blue 0 (0%) 4 (6%) 4 (2%)
radioactive 91 (72%) 33 (53%) 124 (66%)
blue and radioactive 35 (28%) 26 (41%) 61 (32%)
No. of non-sentinel nodes 18 0 18
Tumour excision before 28/103 (27%) 25/51 (49%) 53/154 (34%)
identiﬁcation
Reason of non-identiﬁcation
not explored 6/25 (24%) 7/13 (54%) 13/38 (34%)
high background activity 3/25 (12%) 5/13 (38%) 8/38 (21%)
low radioactive uptake 6/25 (24%) 1/13 (8%) 7/38 (18%)
retrocostal location 7/25 (28%) – 7/38 (19%)
no access to intercostal space 3/25 (12%) – 3/38 (8%)
Table 3 Primary lesion location and tumour-status of the axilla and inter-
nal mammary chain in 555 breast carcinomas with clinically N0-stage
Internal No. of
Axillary mammary/ procedures
Location status chain status (n=555)
IQ/C + + 5
IQ/C + 7 5
IQ/C + NI 1
IQ/C + NV 56
IQ/C 7 +3 *
IQ/C 77 34
IQ/C 7 NI 7
IQ/C 7 NV 91
IQ/C ? + 2
IQ/C ? 7 5
IQ/C ? NI 0
IQ/C ? NV 2
OQ + + 4
OQ + 7 4
OQ + NI 4
OQ + NV 128
OQ 7 +2
OQ 77 23
OQ 7 NI 3
OQ 7 NV 172
OQ ? + 1
OQ ? 7 2
OQ ? NI 0
OQ ? NV 1
IQ=inner-quadrant; OQ=outer-quadrant; C=central; NI=not identiﬁed; NV=not
visualized; +=tumour-positive; 7=tumour-negative; ?=unknown status; *=one
metastasis in the contralateral internal mammary chain.
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British Journal of Cancer (2002) 87(7), 705–710 ã 2002 Cancer Research UKguidelines recommend that node-negative patients with a tumour
larger than 3.0 cm and patients with a high-grade tumour between
1.0 and 3.0 cm in diameter (grade III or mitotic activity index of
greater than 10 per ten high power ﬁelds) receive adjuvant
chemotherapy or hormonal treatment (Bontenbal et al, 2000).
Statistical analysis
The chi square test was used to compare the incidence of lymph
node metastasis between subgroups of patients. Values of
P40.05 were considered to be statistically signiﬁcant. Statistical
analyses were performed with Statistical Package for the Social
Sciences software (SPSS, Chicago, IL, USA).
RESULTS
Sentinel nodes outside level I and II of the axilla were seen on the
lymphoscintigraphy images in 147 patients and in an additional
two patients intraoperatively using patent blue dye. Therefore,
the incidence was 27% (149 out of 549 patients). The lymphatic
drainage patterns are displayed in Table 1. Drainage to the
ipsilateral internal mammary sentinel nodes was observed in 104
patients (19%). A contralateral internal mammary sentinel node
was seen in one additional patient. Interval sentinel nodes were
encountered in 49 patients: intramammary sentinel nodes in 38,
paramammary nodes in two and interpectoral sentinel nodes in
nine patients. Twelve patients had sentinel nodes in the infraclavi-
cular region and three in the supraclavicular region.
At least one non-axillary sentinel node was excised in 128 out of
149 patients (86%). The results of the surgical identiﬁcation of
sentinel nodes outside level I and II of the axilla are displayed in
Table 2. High background radioactivity from tracer remaining at
the injection site necessitated segmental excision of the primary
lesion before the sentinel node could be identiﬁed with the probe
in 53 patients (34%). In eight patients, the extra-axillary sentinel
node could not be identiﬁed because of high background radioac-
tivity that remained after excision of the primary lesion (Table 2).
Sentinel nodes were either blue, radioactive or both. A learning
phase for biopsy of internal mammary chain nodes was observed:
the identiﬁcation rate was 70% in the ﬁrst 30 procedures and
84% in the following procedures.
Metastases were found in 26 of the 128 patients (20%) who
underwent extra-axillary sentinel node excision. Metastases were
found in the internal mammary chain in 16 patients, in the breast
parenchyma in ﬁve, between the pectoral muscles in one, in both
the internal mammary chain and interpectoral fossa in one, in
the infraclavicular fossa in one, in a paramammary sentinel node
in one and in both the supraclavicular fossa and breast parenchyma
in another patient.
Metastases in the internal mammary chain were found in two
out of 132 grade I tumours (2%), in ten out of 240 grade II
tumours (4%), in three out of 132 grade III tumours (2%) and
in two out of 51 tumours with an unknown differentiation grade.
The incidence of internal mammary node metastases was 3% in
both T1 and T2 primary tumours. Internal mammary node metas-
tases were found by immunohistochemistry only in one T1G2
tumour, in two T1G3 tumours and in two T2G2 tumours. The
relation between the tumour-status of the internal mammary chain
sentinel nodes, the axillary status and the primary tumour site is
described in Table 3. Although there was a higher incidence of
internal mammary node metastases in inner quadrant and central
tumours in comparison to outer quadrant lesions (5 vs 2%), this
difference is not signiﬁcant (P=0.073).
Axillary node-positive patients had a higher rate of internal
mammary node involvement than axillary node-negative patients
(4 vs 1%, P=0.042). This difference was more pronounced between
the subgroups of axillary node-positive and node-negative patients
in whom an internal mammary node was excised (50 vs 8%,
P50.001).
The non-axillary sentinel node was the only tumour-positive
lymph node in eleven out of 206 patients (5%) with tumour-posi-
tive sentinel nodes. The location of the metastases, the
characteristics of the primary tumour and the adjuvant therapy
in these eleven patents are described in Table 4.
Of the total of 17 patients with internal mammary node metas-
tasis, eight (47%) had no axillary involvement. Four out of ten
patients (40%) with other non-axillary lymph node metastases also
had a tumour-negative axilla. Considering that one patient had
extra-axillary metastases at more than one site, the non-axillary
sentinel node status had an impact on staging (N1 or N3 instead
of N0) in eleven patients with isolated non-axillary sentinel node
metastases. These metastases were found by routine H&E staining
in 10 patients and by immunohistochemistry only in one patient.
Nine patients with metastases both in the internal mammary senti-
nel node and in the axilla were upstaged from N1 to N3. Overall,
N-staging was changed in 20 out of 149 patients (13%).
Management was modiﬁed in several respects in 26 out of 149
patients (17%), which comprises 5% of the whole sample popula-
tion. Internal mammary chain irradiation was given to seven of
the 149 patients (5%) which they would not have received if the
prior guidelines had been followed. Internal mammary chain irra-
diation was not given to nine patients (6%) who otherwise would
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Table 4 Patients with isolated non-axillary sentinel lymph node metastases
Tumour characteristics Metastasis
Patient D (cm) Grade MAI Location Size (mm) Adjuvant therapy
1 0.8 I 1 IMC 42 Radiotherapy IMC, Tamoxifen
2 0.8 III 11 cIMC 42 Radiotherapy IMC/cIMC, Tamoxifen
3 1.0 I 1 breast 52 Oophorectomy
4 1.3 II 6 breast 42 Radiotherapy IMC, Tamoxifen
5 1.5 II 6 IMC 42 Radiotherapy IMC, Tamoxifen
interpectoral 52
6 1.5 II 1 IMC 42 Radiotherapy IMC, Tamoxifen
7 1.7 I 4 IMC 52 Radiotherapy IMC
8 1.7 I 2 interpectoral 52 Radiotherapy IMC (trial), Oophorectomy
9 1.9 II 6 IMC 42 Radiotherapy IMC, Tamoxifen
10 2.1 II 4 IMC 52 Radiotherapy IMC, Chemotherapy, Tamoxifen
11 2.5 III 36 IMC 42 Radiotherapy IMC/axilla, Chemotherapy
D=diameter; MAI=mitotic activity index (number of mitoses per 10 high power ﬁelds); IMC=ipsilateral internal mammary chain;
cIMC=contralateral internal mammary chain.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 705–710have received such treatment. Eight patients (5%) received adjuvant
chemotherapy or hormone treatment only because of isolated non-
axillary sentinel lymph node metastases (Table 4). The ﬁnding of an
extra-axillary sentinel node prevented axillary lymph node dissection
in ten patients (7%) without a blue or radioactive lymph node in the
axilla. No axillary recurrence has occurred in these ten patients
during a median follow-up of 19 months (range 2–29 months).
DISCUSSION
Sentinel nodes were located outside levels I and II of the axilla in
27% of the patients. Their removal led to a change in the manage-
ment in 17% of them, although this percentage depends on the
protocol for adjuvant therapy that is used (Love, 2002).
Successful visualisation and identiﬁcation of non-axillary senti-
nel nodes requires certain speciﬁc elements of the technique of
lymphatic mapping. Preoperative lymphoscintigraphy is indispen-
sable to detect non-axillary sentinel nodes. An intraparenchymal
tracer administration is essential because intradermal or subdermal
injection will rarely visualise drainage to the internal mammary
chain (Shen et al, 2001; Tanis et al, 2001). Intratumoural injection
with a small volume is preferred to peritumoural injection, because
it limits the extent of the diffusion zone at the injection site
(Valde ￿s Olmos et al, 2000). A single intralesional tracer administra-
tion improves imaging of nearby intraparenchymal sentinel nodes
and enables elimination of background radioactivity by tumour
excision to facilitate subsequent probe identiﬁcation of such nodes
(Table 2).
Harvesting lymph nodes outside the axilla is often a technical
challenging procedure. Internal mammary nodes are generally not
more than a few millimeters in size and are sometimes located
behind a rib. The probe is difﬁcult to handle in the narrow inter-
costal space. The intercostal space is sometimes inaccessible due to
bony deformation or location of the ribs close to each other. A
mere 28% of the internal mammary nodes contained blue dye,
which can be explained by the fact that internal mammary chain
nodes were mostly explored at the end of the procedure at which
time the blue dye may have passed the sentinel node. Additionally,
the supply of blue dye was removed in 27% because the primary
tumour was excised before the sentinel was found. Increasing
experience of the surgeons and possibly the increase in radioactiv-
ity dose and colloid particle concentration resulted in the
improvement of identiﬁcation from 70 to 84% (Valde ￿s Olmos et
al, 2001). Morbidity was limited to an occasional injury to the
internal mammary artery or pleura. In a few patients, a separate
incision of a few centimetres was necessary. Long-term sequelae
were not encountered.
Some of the technical aspects outlined above can explain the large
differences in the reported incidence of non-axillary sentinel nodes
(Uren et al, 1995; Roumen et al, 1997; Borgstein et al, 1998; Chat-
terjee et al, 1998; O’Hea et al, 1998; Reuhl et al, 1998; Rubio et al,
1998; Snider et al, 1998; Hill et al, 1999; Liberman et al, 1999; Miner
et al, 1999; Imoto et al, 2000). Three studies concern results of
biopsy of non-axillary sentinel nodes in a substantial number of
patients (Krag et al, 1998; Johnson et al, 2000; Zurrida et al,
2000). None of these investigators mentioned that the pursuit of
sentinel nodes outside the axilla has an impact on the way patients
are managed. van der Ent et al (2001) reported drainage to the inter-
nal mammary chain in 65 out of 256 patients (25%). Sentinel nodes
at this site could be harvested in 41 patients (63%). These nodes
contained metastasis in eleven patients (27%), resulting in a change
of the subsequent management. The incidence of internal mammary
sentinel nodes in the present study is comparable to Van der Ent’s
observations. The better identiﬁcation rate in the present study
(86 vs 63%) may be due to differences in the technique.
A result of our study design is that the sensitivity cannot be
determined because no completion internal mammary lymph node
dissection was done. Noguchi et al (2000) routinely performed
biopsy of internal mammary nodes in the ﬁrst and second intercos-
tal spaces irrespective of the lymphoscintigraphy results and
concluded that lymphatic mapping is an insensitive technique for
identifying metastases to these nodes. The limited sensitivity in that
study may be explained by the low visualisation rate of internal
mammary sentinel nodes: 9% vs twice as many as in our study.
Our study shows that chasing extra-axillary sentinel nodes
improves staging in 13% of the patients. This has therapeutic
implications, because it is generally accepted that metastases in
these lymph nodes are of prognostic signiﬁcance. The overall survi-
val rates of patients with isolated internal mammary chain
metastases are similar to those with isolated axillary lymph node
involvement. The lowest survival rates are observed in patients with
both axillary and internal mammary node metastases (Handley,
1975; Urban, 1978; Veronesi et al, 1983). Whether these ramiﬁca-
tions of improved staging result in a survival beneﬁt is unknown.
Lacour et al (1983) and Meier et al (1989) performed randomised
studies of extended radical mastectomy vs radical mastectomy and
found no survival difference. Randomised trials of post-mastec-
tomy radiation encompassing the internal mammary nodes did
not result in an improvement in overall survival either (Fisher et
al, 1970; Palmer and Ribeiro, 1985; Høst et al, 1986; Veronesi et
al, 1986; Arriagada et al, 1996). Obfuscating factors of such studies
can be the use of adjuvant systemic treatment and the fact that
internal mammary nodes may be situated in the breast irradiation
ﬁeld (Freedman et al, 2000). Another disadvantage of these studies
is dilution of the potential beneﬁt of the therapy, because the
patients who indeed have lymph node metastases are a minority
within these populations. This was illustrated by Lacour et al
(1976) and Meier et al (1989) who showed a survival beneﬁt in
subgroups of patients with an expected higher incidence of internal
mammary node metastasis.
Traditionally, radiotherapy to the internal mammary chain is
often given in patients with a primary tumour over a certain size
or in a medical quadrant, or in the presence of an involved axilla.
Looking at the primary lesion site and the tumour-status of the
axilla is a fairly crude way to select patients who may have internal
mammary lymph node metastases (Table 3). Biopsy of internal
mammary sentinel nodes allows one to identify patients who
indeed have metastatic disease in these nodes. Surgical treatment
of internal mammary lymph node metastases seems excessive in
this era of conservative surgical treatment of breast cancer but
radiotherapy could be considered. Common sense suggests that
radiotherapy is of no value in case of a tumour-free internal
mammary sentinel node, even in the presence of a large primary
tumour in an inner quadrant with axillary node metastases.
What about patients who do have metastatic disease in an internal
mammary sentinel node? Radiotherapists and medical oncologists
should modify their consensus protocols for radiotherapy and adju-
vant systemic treatment to include these patients. Incorporating the
tumour-status of sentinel nodes outside the axilla in the management
may lead to better patient selection and improved regional control
and survival. One would like to examine these issues in randomised
trials but such trials will be difﬁcult to conduct. For instance, an
informed patient with a tumour-positive internal mammary sentinel
node might be hesitant to accept the risk of being excluded from
adjuvant radiotherapy and systemic treatment.
How should we manage patients with a sentinel node outside
the axilla but without an axillary hot spot on the lymphoscintigra-
phy images? Twenty-three such patients were encountered. Our
policy to explore the axilla and to look for blue or radioactive
lymph nodes resulted in the retrieval of a sentinel node in eight
of these patients. In 10 of the 15 remaining patients, we refrained
from an axillary lymph node dissection, which would have been
performed in the absence of an extra-axillary sentinel node. One
may argue that tracer uptake in an axillary sentinel node was
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British Journal of Cancer (2002) 87(7), 705–710 ã 2002 Cancer Research UKblocked by massive tumour inﬁltration. The risk of overlooking
such a metastasis was reduced by preoperative ultrasound of the
axilla and careful intraoperative palpation of the biopsy wound
(Tanis et al, 2000). No axillary recurrence was seen during
follow-up of these ten patients.
The more accurate staging that is the result from lymphatic
mapping may have repercussions for the TNM staging system.
For instance, an internal mammary lymph node metastasis is
currently classiﬁed as N3. A metastasis in an internal mammary
sentinel node is detected at an early stage and carries a prognosis
that is probably not much worse than is true for an involved senti-
nel node in the axilla, which is classiﬁed as N1. Another subject of
debate is the clinical relevance of micrometastasis, especially if
detected by techniques like step sectioning or immunohistochem-
ical staining (Yarbro et al, 1999). Six of 17 patients (35%) had
an internal mammary node metastasis smaller than 2 mm. A future
evaluation of the TNM system needs to address these issues.
CONCLUSIONS
Lymphatic drainage to sentinel nodes outside levels I and II of the
axilla was found in 27% of the patients. Such nodes contain rele-
vant staging information. Speciﬁc technical elements are essential
to identify and harvest these lymph nodes. Sentinel nodes outside
the axilla could be surgically identiﬁed in the majority of the
patients and contained metastasis in 20%. The extra-axillary senti-
nel node was the only tumour-positive lymph node in 5% of all
patients with tumour-positive sentinel nodes. The postoperative
management was changed in 17% of patients with extra-axillary
sentinel nodes. Despite the uncertain sensitivity we recommend
the pursuit of non-axillary sentinel nodes because of the improved
staging, the therapeutic implications and the minimal morbidity.
ACKNOWLEDGEMENTS
The authors thank the technical staff of the Nuclear Medicine and
Pathology department of The Netherlands Cancer Institute for
their support.
REFERENCES
Arriagada R, Le MG, Rochard F, Contesso G (1996) Conservative treatment
versus mastectomy in early breast cancer: Patterns of failure with 15 years
of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin
Oncol 14: 1558–1564
Bale A, Gardner B, Shende M, Fromowitz F (1999) Can interpectoral nodes
be sentinel nodes? Am J Surg 178: 360–361
Bontenbal M, Nortier JW, Beex LV, Bakker P, Hupperets PS, Nooij MA, van
Veelen H, Vreugdenhil G, Richel DJ, Blijham GH (2000) Adjuvant
systemic therapy for patients with resectable breast cancer: guideline from
the Dutch National Breast Cancer Platform and the Dutch Society for
Medical Oncology. Ned Tijdschr Geneeskd 144: 984–989
Borgstein PJ, Pijpers R, Comans EF, Van Diest PJ, Boom RP, Meijer S (1998)
Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of
lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186:
275–283
Caplan I (1975) Revision anatomique du systeme lymphatique de la glande
mammaire (a propos de 200 cas). Bull Assoc Anat (Nancy) 59: 121–137
Chatterjee S, Menon M, Nicolo G, Carli F, Villa G, Buffoni F, Badellino F
(1998) Sentinel node biopsy in primary breast cancer: a prospective assess-
ment of two complementary techniques. Eur J Surg Oncol 24: 615–616
Cody III HS, Egeli RA, Urban JA (1984) Rotter’s node metastases. Therapeu-
tic and prognostic considerations in early breast carcinoma. Ann Surg 199:
266–270
Cody III HS, Urban JA (1995) Internal mammary node status: a major prog-
nosticator in axillary node-negative breast cancer. Ann Surg Oncol 2: 32–
37
Cox CE, Bass S, Ku NN, Berman CG, Shons AR, Yeatman T, Reintgen DS
(1998) Sentinel lymphadenectomy: a safe answer to less axillary surgery?.
Recent Results Cancer Res 152: 170–179
Dixon JM, Dobie V, Chetty U (1993) The importance of interpectoral nodes
in breast cancer. Eur J Cancer 29: A334–A336
Doting MHE, Jansen L, Nieweg OE, Piers DA, Tiebosch ATMG, Schraffordt
Koops H, Rutgers EJT, Kroon BBR, Peterse JL, Valde ￿s Olmos RA, De Vries
J (2000) Lymphatic mapping with intra-lesional tracer administration in
breast cancer patients. Cancer 88: 2546–2552
Fisher B, Slack NH, Cavanaugh PJ, Gardner B, Ravdin RG (1970) Postopera-
tive radiotherapy in the treatment of breast cancer: Results of the NSABP
clinical trial. Ann Surg 172: 711–728
Freedman GM, Fowble BL, Nicolaou N, Sigurdson ER, Torosian MH, Boraas
MC, Hoffman JP (2000) Should internal mammary lymph nodes in breast
cancer be a target for the radiation oncologist?. Int J Radiat Oncol Biol Phys
46: 805–814
Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass
EC, Turner RR (2000) Prospective observational study of sentinel lympha-
denectomy without further axillary dissection in patients with sentinel
node-negative breast cancer. J Clin Oncol 18: 2553–2559
Handley RS (1975) Carcinoma of the breast. Ann R Coll Surg Engl 57: 59–66
Hill AD, Tran KN, Akhurst T, Yeung H, Yeh SD, Rosen PP, Borgen PI, Cody
III HS (1999) Lessons learned from 500 cases of lymphatic mapping for
breast cancer. Ann Surg 229: 528–535
Høst H, Brennhovd IO, Loeb M (1986) Postoperative radiotherapy in breast
cancer – Long-term results from the Oslo study. Int J Radiat Oncol Biol
Phys 12: 727–732
Hyman LJ, Abellera M (1974) Carcinomatous lymph nodes within breast
parenchyma. Arch Surg 109: 759–761
Imoto S, Fukukita H, Murakami K, Ikeda H, Moriyama N (2000) Pilot study
on sentinel node biopsy in breast cancer. J Surg Oncol 73: 130–133
Johnson N, Soot L, Nelson J, Franzini D, Vea H, Gruner S, Kulawiak L,
Young K (2000) Sentinel node biopsy and internal mammary lymphatic
mapping in breast cancer. Am J Surg 179: 386–388
Krag DN, Weaver DL, Ashikaga T, Moffat FL, Klimberg VS, Shriver CD, Feld-
man SM, Kusminsky R, Gadd M, Kuhn J, Harlow SP, Beitsch PD (1998)
The sentinel node in breast cancer – a multicenter validation study. N Engl
J Med 339: 941–946
Lacour J, Bucalossi P, Caceres E, Jacobelli G, Koszarowski T, Le MG,
Rumeau-Rouquette C, Veronesi U (1976) Radical mastectomy versus radi-
cal mastectomy plus internal mammary dissection. Five-year results of an
international cooperative study. Cancer 37: 206–214
Lacour J, Le MG, Caceres E, Koszarowski T, Veronesi U, Hill C (1983) Radi-
cal mastectomy versus radical mastectomy plus internal mammary
dissection. Ten year results of an international cooperative trial in breast
cancer. Cancer 51: 1941–1943
Liberman L, Cody III HS, Hill AD, Rosen PP, Yeh SD, Akhurst T, Morris EA,
Abramson AF, Borgen PI, Dershaw DD (1999) Sentinel lymph node biopsy
after percutaneous diagnosis of nonpalpable breast cancer. Radiology 211:
835–844
Love RR (2002) Meeting highlights: international consensus panel on the
treatment of primary breast cancer. J Clin Oncol 20: 879–880
Meier P, Ferguson DJ, Karrison T (1989) A controlled trial of extended radi-
cal versus radical mastectomy. Ten-year results. Cancer 63: 188–195
Miner TJ, Shriver CD, Jaques DP, Maniscalco-Theberge ME, Krag DN (1999)
Sentinel lymph node biopsy for breast cancer: the role of previous biopsy
on patient eligibility. Am Surg 65: 493–498
C
l
i
n
i
c
a
l
Non-axillary sentinel nodes in breast cancer
PJ Tanis et al
709
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 705–710Nathanson SD, Wachna L (1999) The intramammary node: a potential cause
of false negative sentinel nodes in breast cancer. Eur J Nucl Med 26(Suppl):
S72–S72 (Abstract)
Noguchi M, Tsugawa K, Miwa K, Yokoyama K, Nakajima Ki, Michigishi T,
Minato H, Nonomura A, Taniya T (2000) Sentinel lymph node biopsy
in breast cancer using blue dye with or without isotope localization. Breast
Cancer 7: 287–296
O’Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, Borgen PI,
Cody III HS (1998) Sentinel lymph node biopsy in breast cancer: initial
experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg
186: 423–427
Palmer MK, Ribeiro GG (1985) Thirty four year follow-up of patients with
breast cancer in clinical trial of postoperative radiotherapy. Br Med J
291: 1088–1091
Reuhl T, Kaisers H, Markwardt J, Haensch W, Hohenberger P, Schlag PM
(1998) Axillary node removal in clinical node-negative breast carcinoma.
Can its indication be individualized by ‘sentinel node’ detection?. Dtsch
Med Wochenschr 123: 583–587
Roumen RMH, Valkenburg JG, Geuskens LM (1997) Lymphoscintigraphy
and feasibility of sentinel node biopsy in 83 patients with primary breast
cancer. Eur J Surg Oncol 23: 495–502
Rubio IT, Korourian S, Cowan C, Krag DN, Colvert M, Klimberg VS (1998)
Sentinel lymph node biopsy for staging breast cancer. Am J Surg 176: 532–
537
Rull M, Fraile M, Alastrue A, Castella E, Calatrava A, Riba J, Julian FJ, Barna-
das A (1999) Histologically invaded intramammary sentinel node, but no
metastases found on axillary dissection. Eur J Surg 165: 1100–1102
Shen P, Glass EC, DiFronzo LA, Giuliano AE (2001) Dermal versus intrapar-
enchymal lymphoscintigraphy of the breast. Ann Surg Oncol 8: 241–248
Snider H, Dowlatshahi K, Fan M, Bridger WM, Rayudu G, Oleske D (1998)
Sentinel node biopsy in the staging of breast cancer. Am Surg 176: 305–
310
Tanis PJ, Nieweg OE, Merkus JL, Peterse JL, Kroon BBR (2000) False negative
sentinel node procedure established through palpation of the biopsy
wound. Eur J Surg Oncol 26: 714–715
Tanis PJ, Nieweg OE, Valde ￿s Olmos RA, Kroon BBR (2001) Anatomy and
physiology of lymphatic drainage of the breast from the perspective of
sentinel node biopsy. J Am Coll Surg 192: 399–409
Urban JA (1978) Management of operable breast cancer. The surgeon’s view.
Cancer 42: 2066–2077
Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G,
Niesche FW, Renwick SB (1995) Mammary lymphoscintigraphy in breast
cancer. J Nucl Med 36: 1775–1780
Valde ￿s Olmos RA, Jansen L, Hoefnagel CA, Nieweg OE, Muller SH, Rutgers
EJT, Kroon BBR (2000) Evaluation of mammary lymphoscintigraphy by
single intratumoral injection for sentinel node identiﬁcation. J Nucl Med
41: 1500–1506
Valde ￿s Olmos RA, Tanis PJ, Hoefnagel CA, Nieweg OE, Jansen L, Muller SH,
Rutgers EJT, Kooi MLK, Kroon BBR (2001) Improved sentinel node visua-
lization in breast cancer by optimizing the colloid particle concentration
and tracer dosage. Nucl Med Commun 22: 579–586
van der Ent FW, Kengen RA, van der Pol HA, Povel JA, Stoeken HJ, Hoofwijk
AG (2001) Halsted revisited: internal mammary sentinel lymph node
biopsy in breast cancer. Ann Surg 234: 79–84
Veronesi U, Cascinelli N, Bufalino R, Morabito A, Greco M, Galluzzo D,
Delle Donne V, De Lellis R, Piotti P, Sacchini V (1983) Risk of internal
mammary lymph node metastases and its relevance on prognosis of breast
cancer patients. Ann Surg 198: 681–684
Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, Dei Bei E,
Greco M, Magni A, Merson M, Quagliuolo V (1987) Distribution of axil-
lary node metastases by level of invasion. An analysis of 539 cases. Cancer
59: 682–687
Veronesi U, Zucali R, Luini A (1986) Local control and survival in early
breast cancer: The Milan trial. Int J Radiat Oncol Biol Phys 12: 717–720
Yarbro JW, Page DL, Fielding LP, Partridge EE, Murphy GP (1999) American
Joint Committee on Cancer prognostic factors consensus conference.
Cancer 86: 2436–2446
Zurrida S, Galimberti V, Orvieto E, Robertson C, Ballardini B, Cremonesi M,
de Cicco C, Luini A (2000) Radioguided sentinel node biopsy to avoid axil-
lary dissection in breast cancer. Ann Surg Oncol 7: 28–31
C
l
i
n
i
c
a
l
Non-axillary sentinel nodes in breast cancer
PJ Tanis et al
710
British Journal of Cancer (2002) 87(7), 705–710 ã 2002 Cancer Research UK